Volatile components of cigarette smoke: Effect of acrolein and acetaldehyde on human gingival fibroblasts in vitro

被引:43
作者
Cattaneo, V
Cetta, G
Rota, C
Vezzoni, F
Rota, MT
Gallanti, A
Boratto, R
Poggi, P
机构
[1] Univ Pavia, Dept Periodontol, I-27100 Pavia, Italy
[2] Univ Pavia, Dept Biochem A Castellani, I-27100 Pavia, Italy
[3] Univ Pavia, Dept Morphol Eidol & Clin Sci, Sect Human Normal Anat, I-27100 Pavia, Italy
关键词
acetaldehyde/adverse effects; acrolein/adverse effects; fibroblasts; smoking/adverse effects; periodontal diseases/etiology; risk factors; cell culture;
D O I
10.1902/jop.2000.71.3.425
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Tobacco and some of its volatile and non-volatile components have been found to affect many types of cells including gingival fibroblasts. Since normal gingival fibroblast functioning is fundamental to the maintenance of the periodontal connective tissue, as well as to wound healing, we examined the effect of acrolein and acetaldehyde, volatile components of cigarette smoke, on proliferation, attachment, and ultrastructure of human gingival fibroblasts (HGFs) in culture. Methods: Human gingival fibroblast (HGF) strains derived from healthy individuals with non-inflamed gingiva were used in this study. The cells were incubated in the presence of different concentrations of acrolein and acetaldehyde. Cell attachment and proliferation were evaluated after incubation for 3 hours and 5 days, respectively. In addition, the cells were examined with a transmission electron microscope in order to evaluate their morphology. Results: The results show that acrolein and acetaldehyde produced dose-dependent inhibition of HGF attachment and proliferation. The cytotoxic effect was, however, reversible when both substances were removed, after 3 days, from the medium. The main ultrastructural finding for the HGF cytoplasm was the presence of vacuoles and lysosomal structures that became prominent with increasing concentration of acrolein and acetaldehyde. Conclusions: Our experimental data suggest that acrolein and acetaldehyde, volatile components of tobacco smoke, are detrimental to HGF survival and consequently to the oral connective tissue. According to our morpho-functional evidence, these findings corroborate clinical and epidemiological investigations demonstrating smoke as a risk factor in the development of periodontal disease.
引用
收藏
页码:425 / 432
页数:8
相关论文
共 48 条
[1]   Nicotine-induced alterations in human primary periodontal ligament and gingiva fibroblast cultures. [J].
Alpar B. ;
Leyhausen G. ;
Sapotnick A. ;
Günay H. ;
Geurtsen W. .
Clinical Oral Investigations, 1998, 2 (1) :40-46
[2]   Relationship between smoking and dental status in 35-, 50-, 65-, and 75-year-old individuals [J].
Axelsson, P ;
Paulander, J ;
Lindhe, J .
JOURNAL OF CLINICAL PERIODONTOLOGY, 1998, 25 (04) :297-305
[3]   Tobacco and smoking: Environmental factors that modify the host response (immune system) and have an impact on periodontal health [J].
Barbour, SE ;
Nakashima, K ;
Zhang, JB ;
Tangada, S ;
Hahn, CL ;
Schenkein, HA ;
Tew, JG .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1997, 8 (04) :437-460
[4]   CIGARETTE-SMOKING AND ALVEOLAR BONE HEIGHT IN SUBJECTS WITH A HIGH STANDARD OF ORAL HYGIENE [J].
BERGSTROM, J ;
ELIASSON, S .
JOURNAL OF CLINICAL PERIODONTOLOGY, 1987, 14 (08) :466-469
[5]   CIGARETTE-SMOKING AS RISK FACTOR IN CHRONIC PERIODONTAL-DISEASE [J].
BERGSTROM, J .
COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 1989, 17 (05) :245-247
[6]   CIGARETTE-SMOKING AND PERIODONTAL BONE LOSS [J].
BERGSTROM, J ;
ELIASSON, S ;
PREBER, H .
JOURNAL OF PERIODONTOLOGY, 1991, 62 (04) :242-246
[7]   Nicotine and smokeless tobacco effects on gingival and peripheral blood mononuclear cells [J].
Bernzweig, E ;
Payne, JB ;
Reinhardt, RA ;
Dyer, JK ;
Patil, KD .
JOURNAL OF CLINICAL PERIODONTOLOGY, 1998, 25 (03) :246-252
[8]   Smoking and crevicular fluid levels of IL-6 and TNF-α in periodontal disease [J].
Boström, L ;
Linder, LE ;
Bergström, J .
JOURNAL OF CLINICAL PERIODONTOLOGY, 1999, 26 (06) :352-357
[9]  
BRIDGES RB, 1980, INFECT IMMUN, V29, P1096
[10]  
BROCK N, 1976, CANCER TREAT REP, V60, P301